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http://dx.doi.org/10.1016/j.pedneo.2Background: Wilms tumor is the most common primary renal malignancy occurring in child-
hood. Significant improvement has been made in the treatment of children with Wilms tumor.
However, the treatment of patients with non-Wilms renal tumors remains challenging.
Methods: Between 1991 and 2010, 70 children with renal tumors were diagnosed at a single
institution. Fifty-four patients were histologically confirmed and divided into three groups,
including 42 Wilms tumors, seven clear cell sarcomas of kidney, and five malignant rhabdoid
tumors. Most patients underwent unilateral nephrectomy and lymph node sampling followed
by adjuvant chemotherapy. Twenty-one of these patients subsequently received radiotherapy.
Results: During follow-up, 12 patients died of progressive disease and one died of operative
mortality. One patient with unilateral pleural metastases subsequently underwent hematopoi-
etic stem cell transplantation. The median survival time of all patients was 88 months.ematology and Oncology, Department of Pediatrics, Chang Gung Children’s Hospital, 5 Fu-Shin Street,
g.tw (T.-H. Jaing).
an Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
013.09.007
176 T.-H. Jaing et alChildren under 2 years of age at diagnosis with Wilms tumor or clear cell sarcoma of kidney had
an excellent survival rate of 100% compared to the 0% survival rate of MRT.
Conclusion: Younger age at diagnosis bore a better prognosis than did older age, whereas a
diagnosis of malignant rhabdoid tumor portended a worse prognosis. Younger patients and
appropriate treatment may have contributed to the improved prognosis of clear cell sarcoma
of kidney.
Copyright ª 2013, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Pediatric renal tumors represent a relatively common group
of childhood solid neoplasms, in which both diagnosis and
treatment are highly dependent on the histopathological
findings.1e3 Wilms tumor (WT) is the most common renal
tumor in children and represents approximately 95% of all
pediatric renal malignancies.4 WT was also the first solid
malignancy in which the value of adjuvant chemotherapy
was established. Treatment for WT is one of the perceived
successes of pediatric oncology, with long-term survival in
>90% of the cases for localized disease and >70% of the
cases for metastatic disease.5 In addition, a few patients
have genetic abnormalities predisposing to WT develop-
ment, which result in renal dysfunction in the long term and
may be exacerbated by cancer treatment regimens.
Awareness of late consequences of cancer treatment is
important, as early recognition can improve outcome.6
Malignant renal tumor histology is the most important
factor in determining prognosis.7,8 Successful treatment of
malignant renal tumors requires meticulous attention to
correct staging of the tumor and good communication among
the pediatric surgeon, pathologist, and oncologist.9e11 The
aim of this study is to illustrate our clinical experience in the
long-term follow-up of children with three common malig-
nant renal tumors treated according to the Taiwan Pediatric
Oncology Group (TPOG) W91 and W97 protocols.
2. Materials and Methods
Throughout the period 1991e2010, 70 children with histo-
logical confirmation of renal tumors were treated at Chang
Gung Children’s Hospital, Taoyuan, Taiwan. We reviewed
the charts of these patients throughout the whole disease
course, including long-term follow-up, paying particular
attention to the details of postoperative stage, patholog-
ical findings, and outcomes. Sixteen patients were
excluded because of benign histology or non-Wilms renal
tumors other than clear cell sarcoma of kidney (CCSK) or
malignant rhabdoid tumor (MRT). There were renal cell
carcinomas in six cases, renal sarcoma in five cases, para-
ganglioma in two cases, angiomyolipoma in one case,
mesoblastic nephroma in one case, and renal tumor without
histological diagnosis in one case.
2.1. Treatment
The analyzed patients were treated by a consistent policy
of surgical removal with histological verification followedby chemotherapy with or without radiotherapy. There were
32 boys and 22 girls with a median age of 25 months (range
2e176 months). All patients underwent nephrectomy and
lymph node sampling followed by adjuvant chemotherapy.
Chemotherapy regimens included the TPOG W91 and W97
protocols varying according to treatment era. TPOG W91
was the first WT study of the TPOG. This study began in July
1991 and ended in December 1997. TPOG W97 was a revised
version of TPOG W91. The important revisions are as fol-
lows: used single dose of dactinomycin; shortened duration
of treatment for stage I disease; preoperative chemo-
therapy for patients with bilateral disease; patients with
stage IV disease; massive unresectable tumor or significant
caval extension; no preoperative chemotherapy for infants
less than 6 months of age; introduction of etoposide and
carboplatin into protocols for high-risk patients. According
to the original staging criteria stipulated in the protocol, 21
patients received postoperative radiotherapy plus chemo-
therapy and the others received chemotherapy alone.
2.2. Statistical analyses
Data were abstracted on patient demographics, tumor
histology, staging, number of lymph nodes sampled, and
disease-specific and overall patient outcomes. Statistical
analyses were performed with SPSS for Windows, version
18.0 (SPSS Inc., Chicago, IL, USA). A p-value <0.05 was
considered statistically significant. Overall survival is
defined as the time from randomization until death from
any cause, and it is measured in the intent-to-treat popu-
lation. Disease-free survival is defined as the time from
cancer diagnosis until recurrence of tumor or death from
any cause.
The time to tumor recurrence was determined by follow-
up images. KaplaneMeier survival analysis was conducted
to determine actuarial survival; 95% confidence intervals
(95% CIs) were calculated for the survival estimation
(Figure 1). Owing to the observational nature of the study,
institutional review board approval was granted by expe-
dited review. The data were further crosschecked with the
TPOG database that collected all the pathology reports of
cancer in the territory.
3. Results
Overall, 54 cases were identified. The main clinical char-
acteristics of all the patients are summarized in Table 1.
The histological diagnosis was WT in 42 patients (78%), CCSK
in seven patients (13%), and MRT in five patients (9%). The
Months
Pr
op
or
tio
n 
su
rv
ivi
ng
0 50 100 150 200
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Overall survival, Wilms tumor
Overall survival, CCSK
Overall survival, Rhabdoid tumor
Months
Pr
o
po
rti
on
 s
ur
vi
vi
ng
0 50 100 150 200
0.
0
0.
2
0.
4
0.
6
0.
8
1.
0
Disease-free survival, Wilms tumor
Disease-free survival, CCSK
Disease-free survival, Rhabdoid tumor
Figure 1 Overall and disease-free survival by KaplaneMeier estimates. CCSK Z clear cell sarcoma of kidney.
Malignant renal tumors in childhood 177tumor weight also varied widely, from 70 g to 1500 g. The
tumors were confined to one kidney in 50 cases (24 left, 26
right), and both kidneys in four cases.
Of the children diagnosed with WT, 16 (30%) had stage I
disease, 10 (19%) had stage II, nine (17%) had stage III, two
(4%) had stage IV, four (7%) had stage V disease, and one
was unclassified due to insufficient information. For pa-
tients with CCSK, four (7%) had stage I, one (2%) had stage
II, one (2%) had stage III, and one (2%) had stage IV. For
patients with MRT, five (9%) were classified as stage IV with
distant metastasis. Two patients had lung metastases at the
initial presentation; one of them subsequently developed
brain metastasis. For the other three patients, two had
liver metastasis and one had brain metastasis at diagnosis.
Seven associated anomalies were present in six patients
(11.1%) as shown in Table 2. One patient had more than one
anomaly. Moreover, a positive correlation between tumorsize and outcome was not observed in our series. There was
no statistically significant difference in outcome between
the two protocols used.
During follow-up, 12 patients died of progressive disease
and one died of operative mortality. Of those 54 patients,
10 patients had documented pulmonary metastasis. Lung
metastasis was confirmed by chest computed tomography
(CT) scan at diagnosis in five patients (9.3%), and the other
five patients were finally diagnosed by radiological follow-
up examinations. Nine of the 10 patients with lung metas-
tasis at diagnosis or follow-up eventually died of metastatic
disease. One patient with unilateral pleural metastases
required high-dose chemotherapy and tandem autologous
stem cell rescue, who subsequently underwent allogeneic
hematopoietic stem cell transplantation.
The collective median survival time of all patients was
88 months. For patients with WT and CCSK, the 5-year
Table 1 Demographics and clinical characteristics.
n %
Sex
Male 32 59
Female 22 41
Laterality
Left 25 46
Right 25 46
Bilateral 4 8
NWTSG stage
Stage I 20 37
Stage II 11 20
Stage III 10 19
Stage IV 8 15
Stage V 4 7
Unknown 1 2
Tumor weight
500 g 28 52
500 g 14 26
Unknown 12 22
Tumor histology
Wilms tumor 42 78
Clear cell sarcoma of kidney 7 13
Malignant rhabdoid tumor 5 9
Adjuvant therapy
Chemotherapy 54 100
Radiotherapy 21 39
Tumor recurrence
No 37 69
Yes 17 31
NWTSG Z National Wilms Tumor Study Group.
Table 2 Associated anomalies in the six patients with
Wilms tumor in this study.
Associated anomalies n
Hypospadias 1
Hydronephrosis 1
Congenital cataracts 1
Congenital heart disease 1
Dysmorphism 2
Congenital hydrocephalus 1
Table 3 Overall survival and disease-free survival of patient su
Variables Overall survival (mo) p
Histology
WT 162.79  10.35
CCSK 181.57  23.54 <
MRT 3.80  1.02
WT and CCSK
Age 2 y Unestimated (no event case) <
Age >2 y 138.11  15.95
*p-value calculated by log-rank test.
CCSK Z clear cell sarcoma of kidney; MRT Z malignant rhabdoid tum
178 T.-H. Jaing et aloverall survival rates were 83.3% and 85.7%, respectively.
Moreover, children under 2 years of age at diagnosis with
WT or CCSK had an excellent survival rate of 100% compared
with that of MRT, which was usually fatal within 1 year of
diagnosis (Table 3).
4. Discussion
WT is one of the successes of pediatric oncology, with an
overall cure rate of over 85%, using relatively simple thera-
pies.12,13 Despite these successes, controversy continues
regarding the optimal management of children with unilat-
eral, favorable histology WT.14,15 Two different approaches
have been recommended by different investigators: imme-
diate nephrectomy or pre-nephrectomy chemotherapy fol-
lowed by delayed nephrectomy.4,16 However, it is difficult
to compare the two approaches head-to-head precisely.
The overridingmessage is that most patients withWTsurvive
long term, regardless of the sequence of therapeutic in-
terventions. The data reported here suggest that younger
patients with WT or CCSK generally have a good prognosis.
The role of high-dose chemotherapy followed by stem cell
rescue or transplantation is undefined in recurrent WT
patients.17e19 However, high-dose chemotherapy intensifi-
cation and hematopoietic stem cell support could be an
effective treatment for patients with WT who experience
relapse.20,21
WT is the most common renal tumor of childhood.
However, other epithelial, mesenchymal, and neuro-
ectodermal neoplasms may also arise in the kidney during
childhood, several of which show specific age distribu-
tions.22,23 In the past, CCSK was initially considered an
unfavorable histology WT variant. However, in 1970 it was
recognized as a separate clinicopathological entity by
Kidd.24 Marsden et al25 subsequently called the tumor the
“bone metastasizing renal tumor of childhood”, and Beck-
with and Palmer26 were the first to use the term “clear cell
sarcoma”.
In our study, the outcome of CCSK seems not inferior to
the outcome of WT described in the literature.27e29 There
are two reasons which may explain why results differ. First,
our patients who were treated with chemoradiation expe-
rienced an improved relapse-free survival from a longer
course of therapy when using vincristine, doxorubicin, and
dactinomycin. The other reason is that no CCSK patient had
bilateral disease (stage V) or positive CT or magneticbgroups.
* Disease-free survival (mo) p*
136.13  11.54
0.001 177.86  26.98 0.001
2.60  0.51
0.004 198.30  8.51 0.003
110.28  16.08
or; WT Z Wilms tumor.
Malignant renal tumors in childhood 179resonance imaging of the brain at diagnosis. CCSK has a
unique constellation of chromosomal and molecular fea-
tures and should no longer be viewed as an unfavorable
histological variant of WT.8 However, it is essential to
acknowledge the limitation of this study is that it is a single
institutional study with a small cohort size.
MRT is an uncommon tumor that may occur outside of
renal and central nervous system sites. Particularly trou-
bling are the dismal survival rates for the very young.30
However, in the five patients who had distant metastasis
at diagnosis which contributed to their worse prognosis,
subsequent mortality was reasonable. Two patients pre-
senting with central nervous system metastases at diagnosis
had an even worse prognosis.
In conclusion, reduction of tumor volume due to pre-
operative chemotherapy facilitates tumor removal by sur-
gery and may prevent intraoperative tumor spill and the
deleterious effects of radiation in young children.5,31 Chil-
dren under 2 years of age at diagnosis with WT or CCSK had
an excellent survival rate of 100% compared to that of MRT.
It is possible to interpret that as the younger patients
having been diagnosed at earlier stages of the disease.
Regardless of location, all MRT are highly aggressive, have a
poor prognosis, and tend to occur in children less than 2
years of age. Younger age at diagnosis bore a better prog-
nosis than did older age, whereas a diagnosis of MRT por-
tended a worse prognosis. Treatment strategies need to be
refined for patients with MRT, although the number of
analyzed cases is too small to draw definitive conclusions.
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